Efficacy of Xiidra in Dry Eye Disease After Collagen Cross Linking

Benha University

Status and phase: Unknown; Phase 4

Conditions: Corneal Disease

Treatments: Drug: Xiidra 5% Ophthalmic Solution

Study type: Interventional

Funder types: Other

Identifiers

NCT05045053

Hamaky17

Details and patient eligibility

About

dry eye disease after corneal collagen cross linking affect ocular function leading to reduced vision, photophobia, glare, halos, and foreign body sensation.

Full description

first group of patients were treated with 0.5 % xiidra twice daily and artificial tears for 6 months.Second group treated with artificial tears for 6 months. the treatment starts after corneal collagen cross linking in both groups ,Baseline and post-treatment full ophthalmic examination was done.

Enrollment: 40 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• corneal collagen cross linking

Exclusion criteria

• systemic or ocular diseases ,previous ocular surgery, corneal pathology and contact lens wearers

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

40 participants in 2 patient groups

xiidra group

Experimental group

Description:

patients are treated with 0.5 % xiidra twice daily and artificial tears for 6 months after corneal collagen cross linking

Treatment:

Drug: Xiidra 5% Ophthalmic Solution

control group

No Intervention group

Description:

patient are treated with artificial tears for 6 months after corneal collagen cross linking in both groups